Targeted Molecular Tests for Urinary Tract Infections and Epstein-Barr Virus
Timely diagnosis makes a direct difference in patient care. In cases of urinary tract infections (UTIs) and Epstein-Barr Virus (EBV) infections, doctors often need precise results quickly to start the right treatment. Traditional methods can be slow or uncertain, and in many situations, decisions are made before lab results are available. This is where molecular testing helps. 3B BlackBio Biotech India Ltd has developed two tests that meet this need: the UTI Panel Test and the EBV PCR Test.
The UTI Panel Test is a real-time PCR assay that detects multiple bacterial pathogens in a single urine sample. UTIs are common and often treated with antibiotics based on symptoms alone. This practice increases the risk of giving the wrong treatment, especially when resistant bacteria are involved. Standard urine culture can take up to 48 hours and may not always identify the organism clearly.
This test simplifies the process. It detects bacteria like Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis, and others in one go. It can deliver accurate results in a matter of hours, making it useful in both outpatient and hospital settings. Doctors can rely on the findings to prescribe targeted antibiotics instead of broad-spectrum ones, which helps reduce antimicrobial resistance and avoid unnecessary side effects. The UTI Panel Test improves both the speed and accuracy of diagnosis, leading to better decisions.
The EBV PCR Test works on a different challenge. Epstein-Barr Virus is commonly present in the population and typically remains inactive in the body after the first infection. For the majority of individuals, EBV leads to either mild symptoms or none at all. But in patients with weak immune systems, such as transplant recipients or those undergoing chemotherapy, the virus can become active again and cause serious complications.
Using real-time PCR, this test detects and quantifies EBV DNA in blood samples. This information is important in monitoring high-risk patients. An increasing viral load can signal the early stages of EBV-related disorders, including post-transplant lymphoproliferative disease. With early detection, doctors can begin treatment or adjust therapy before complications develop.
The EBV PCR Test is also helpful in confirming diagnosis in cases of suspected infectious mononucleosis or other EBV-linked conditions. It gives doctors a clear measurement of the virus in the bloodstream, which supports decisions around antiviral treatment and follow-up care.
Both tests are built for reliability and routine use. The UTI Panel Test and EBV PCR Test are compatible with standard PCR instruments and follow validated protocols. They include internal controls to ensure result quality and reduce the risk of false negatives. Laboratories using these tests benefit from fast turnaround times and fewer repeat tests.
3B BlackBio has developed these tests to meet the practical demands of everyday diagnostic work in hospitals and labs. The UTI Panel Test helps manage one of the most common infections with more precision, avoiding trial-and-error antibiotic use. The EBV PCR Test supports clinicians in monitoring high-risk patients where timing and accuracy are critical.
